Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Acute kidney injury HP kidney injury MESHD in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study

    Authors: Guanhua Xiao; Hongbin Hu; Feng Wu; Tong Sha; Qiaobing Huang; Haijun Li; Jiafa Han; Wenhong Song; Zhongqing Chen; Zhenhua Zeng

    doi:10.1101/2020.04.06.20055194 Date: 2020-04-08 Source: medRxiv

    Background: The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury HP acute kidney injury MESHD ( AKI MESHD) among individuals with COVID-19. Methods: This observational study, included data on all patients with clinically confirmed COVID-19 admitted to Hankou Hospital, Wuhan, China from January 5 to March 8, 2020. Data were extracted from clinical and laboratory records. Follow-up was censored on March 8, 2020. This is a single-center, retrospective, observational study. Patients clinically confirmed COVID-19 and admitted to Hankou Hospital, Wuhan, China from January 5 to March 8, 2020 were enrolled. We evaluated the association between changes in the incidence of AKI MESHD and COVID-19 disease and clinical outcomes by using logistic regression models. Results: A total of 287 patients, 55 with AKI MESHD and 232 without AKI MESHD, were included in the analysis. Compared to patients without AKI MESHD, AKI MESHD patients were older, predominantly male TRANS, and were more likely to present with hypoxia MESHD and have pre-existing hypertension HP hypertension MESHD and cerebrovascular disease MESHD. Moreover, AKI MESHD patients had higher levels of white blood SERO cells, D-dimer, aspartate aminotransferase, total bilirubin, creatine kinase, lactate dehydrogenase, procalcitonin, C-reactive protein, a higher prevalence SERO of hyperkalemia HP hyperkalemia MESHD, lower lymphocyte counts, and higher chest computed tomographic scores. The incidence of stage 1 AKI MESHD was 14.3%, and the incidence of stage 2 or 3 AKI MESHD was 4.9%. Patients with AKI MESHD had substantially higher mortality. Conclusions: AKI MESHD is an important complication of COVID-19. Older age TRANS, male TRANS, multiple pre-existing comorbidities, lymphopenia HP lymphopenia MESHD, increased infection indicators, elevated D-dimer, and impaired heart and liver functions MESHD were the risk factors of AKI MESHD. AKI MESHD patients who progressed to stages 2 or 3 AKI MESHD had a higher mortality rate. Prevention of AKI MESHD and monitoring of kidney function is very important for COVID 19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.